ArticleRadiology2022
CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes.
Open access · greenAbstract read
In one paragraph
Article in Radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
13.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- The presence of a cribriform pattern is related to poor prognosis in lung adenocarcinoma after surgical resection: A meta-analysis.General thoracic and cardiovascular surgery · 2024Pooled it
- A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma.Immuno-oncology technology · 2026Article
- Body composition radiomics integrated with machine learning to predict prognosis in advanced NSCLC treated with first-line immunochemotherapy and concurrent radiotherapy.BMC pulmonary medicine · 2026Article
- Single and multi-site CT-based radiogenomics analysis of metastatic lung adenocarcinoma and correlations with outcome.European radiology · 2026Article
- An exploratory study on whole-lung radiomics features from computed tomography for prognostic prediction in non-small cell lung cancer with concurrent chemoradiotherapy.Translational cancer research · 2026Article
- Risk factors for pathological invasiveness of non-mucinous invasive pulmonary adenocarcinoma with a maximum diameter of less than or equal to 3 cm in thin-section CT: a retrospective study.Scientific reports · 2026Article
- Radiogenomic landscape of the hallmarks of cancer.Biomarker research · 2026Review
- Radiomic subtypes predict survival and chemotherapy benefit in stage I lung adenocarcinoma: a multicenter study.Insights into imaging · 2026Article
- Diagnosis of Lung Diseases in the Artificial Intelligence Era.International journal of molecular sciences · 2026Article
- Article
- Novel insights into predicting the presence of micropapillary and solid components in stage IA lung adenocarcinoma using machine learning models of modifiable risk factors.Annals of medicine · 2025Article
- Radiogenomics: transforming lung cancer care through non-invasive imaging and genomic integration.Medical oncology (Northwood, London, England) · 2025Review
- Imaging and RNA sequencing-based radiogenomic analysis of occult lymph node metastasis and survival in lung adenocarcinoma staged non-metastatic.Communications medicine · 2025Article
- Predicting the prognosis of patients with lung adenocarcinoma treated with third-generation EGFR-TKI alone using nomograms based on CT radiomic and clinicopathological factors.Translational lung cancer research · 2025Article
- Computed tomography-based quantification of intra-tumoral heterogeneity for predicting treatment response to concurrent chemoradiotherapy in non-small cell lung cancer: a multicenter retrospective study.Translational cancer research · 2025Article
- A proof of concept study ofScientific reports · 2025Article
- CT Imaging-based radiomics predicts the pain relief of Strontium-89 in treating tumor-induced bone metastases.Journal of applied clinical medical physics · 2025Article
- Consensus clustering based on CT radiomics has potential for risk stratification of patients with clinical T1 stage lung adenocarcinoma.BMC medical imaging · 2025Article
- Progress and challenges of artificial intelligence in lung cancer clinical translation.NPJ precision oncology · 2025Review
- Image-Based Deep Learning Model for Predicting Lymph Node Metastasis in Lung Adenocarcinoma With CT ≤ 2 cm.Thoracic cancer · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 2 countries.
Rocio Perez-JohnstonFrom the Department of Radiology (R.P., J.A.A., P.G., M.S.G.), Druckenmiller Center for Lung Cancer Research (R.P., K.S.T., N.R., M.S.G., D.R.J.), Thoracic Surgery Service (J.G.C., R.C., J.Z., D.R.J.), Biostatistics Service, Department of Epidemiology and Biostatistics (K.W., K.S.T.), and Department of Pathology (N.R.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 7, New York, NY 10065.ORCID 0000-0001-9063-2615
Jose A Araujo-FilhoFrom the Department of Radiology (R.P., J.A.A., P.G., M.S.G.), Druckenmiller Center for Lung Cancer Research (R.P., K.S.T., N.R., M.S.G., D.R.J.), Thoracic Surgery Service (J.G.C., R.C., J.Z., D.R.J.), Biostatistics Service, Department of Epidemiology and Biostatistics (K.W., K.S.T.), and Department of Pathology (N.R.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 7, New York, NY 10065.ORCID 0000-0002-8627-3661
James G ConnollyFrom the Department of Radiology (R.P., J.A.A., P.G., M.S.G.), Druckenmiller Center for Lung Cancer Research (R.P., K.S.T., N.R., M.S.G., D.R.J.), Thoracic Surgery Service (J.G.C., R.C., J.Z., D.R.J.), Biostatistics Service, Department of Epidemiology and Biostatistics (K.W., K.S.T.), and Department of Pathology (N.R.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 7, New York, NY 10065.
Raul CasoFrom the Department of Radiology (R.P., J.A.A., P.G., M.S.G.), Druckenmiller Center for Lung Cancer Research (R.P., K.S.T., N.R., M.S.G., D.R.J.), Thoracic Surgery Service (J.G.C., R.C., J.Z., D.R.J.), Biostatistics Service, Department of Epidemiology and Biostatistics (K.W., K.S.T.), and Department of Pathology (N.R.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 7, New York, NY 10065.
Karissa WhitingFrom the Department of Radiology (R.P., J.A.A., P.G., M.S.G.), Druckenmiller Center for Lung Cancer Research (R.P., K.S.T., N.R., M.S.G., D.R.J.), Thoracic Surgery Service (J.G.C., R.C., J.Z., D.R.J.), Biostatistics Service, Department of Epidemiology and Biostatistics (K.W., K.S.T.), and Department of Pathology (N.R.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 7, New York, NY 10065.
Kay See TanFrom the Department of Radiology (R.P., J.A.A., P.G., M.S.G.), Druckenmiller Center for Lung Cancer Research (R.P., K.S.T., N.R., M.S.G., D.R.J.), Thoracic Surgery Service (J.G.C., R.C., J.Z., D.R.J.), Biostatistics Service, Department of Epidemiology and Biostatistics (K.W., K.S.T.), and Department of Pathology (N.R.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 7, New York, NY 10065.
Jian ZhouFrom the Department of Radiology (R.P., J.A.A., P.G., M.S.G.), Druckenmiller Center for Lung Cancer Research (R.P., K.S.T., N.R., M.S.G., D.R.J.), Thoracic Surgery Service (J.G.C., R.C., J.Z., D.R.J.), Biostatistics Service, Department of Epidemiology and Biostatistics (K.W., K.S.T.), and Department of Pathology (N.R.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 7, New York, NY 10065.
Peter GibbsFrom the Department of Radiology (R.P., J.A.A., P.G., M.S.G.), Druckenmiller Center for Lung Cancer Research (R.P., K.S.T., N.R., M.S.G., D.R.J.), Thoracic Surgery Service (J.G.C., R.C., J.Z., D.R.J.), Biostatistics Service, Department of Epidemiology and Biostatistics (K.W., K.S.T.), and Department of Pathology (N.R.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 7, New York, NY 10065.ORCID 0000-0002-5754-7352
Natasha RekhtmanFrom the Department of Radiology (R.P., J.A.A., P.G., M.S.G.), Druckenmiller Center for Lung Cancer Research (R.P., K.S.T., N.R., M.S.G., D.R.J.), Thoracic Surgery Service (J.G.C., R.C., J.Z., D.R.J.), Biostatistics Service, Department of Epidemiology and Biostatistics (K.W., K.S.T.), and Department of Pathology (N.R.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 7, New York, NY 10065.
Michelle S GinsbergFrom the Department of Radiology (R.P., J.A.A., P.G., M.S.G.), Druckenmiller Center for Lung Cancer Research (R.P., K.S.T., N.R., M.S.G., D.R.J.), Thoracic Surgery Service (J.G.C., R.C., J.Z., D.R.J.), Biostatistics Service, Department of Epidemiology and Biostatistics (K.W., K.S.T.), and Department of Pathology (N.R.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 7, New York, NY 10065.ORCID 0000-0003-0304-110X
David R JonesFrom the Department of Radiology (R.P., J.A.A., P.G., M.S.G.), Druckenmiller Center for Lung Cancer Research (R.P., K.S.T., N.R., M.S.G., D.R.J.), Thoracic Surgery Service (J.G.C., R.C., J.Z., D.R.J.), Biostatistics Service, Department of Epidemiology and Biostatistics (K.W., K.S.T.), and Department of Pathology (N.R.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 7, New York, NY 10065.ORCID 0000-0002-3318-0146
Jisc · GBMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSURGICAL ONCOLOGY RESEARCH TRAINING PROGRAMT32CA009501 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Babak J Mehrara · 1985 to 2026
$7.7MBRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinomaR01CA217169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2018 to 2022
$2.5MTargeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinomaR01CA240472 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2019 to 2023
$2.4MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA217169NCI NIH HHS R01 CA240472NCI NIH HHS T32 CA009501
Abstract
Background A preoperative predictive model is needed that can be used to identify patients with lung adenocarcinoma (LUAD) who have a higher risk of recurrence or metastasis. Purpose To investigate associations between CT-based radiomic consensus clustering of stage I LUAD and clinical-pathologic features, genomic data, and patient outcomes. Materials and Methods Patients who underwent complete surgical resection for LUAD from April 2014 to December 2017 with preoperative CT and next-generation sequencing data were retrospectively identified. Comprehensive radiomic analysis was performed on preoperative CT images; tumors were classified as solid, ground glass, or mixed. Patients were clustered into groups based on their radiomics features using consensus clustering, and clusters were compared with tumor genomic alterations, histopathologic features, and recurrence-specific survival (Kruskal-Wallis test for continuous data, χ
Indexed as
Adenocarcinoma of LungLung NeoplasmsAgedFemaleHumansMaleMiddle AgedPhosphatidylinositol 3-KinasesRetrospective StudiesTomography, X-Ray Computed
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.